KalVista Pharmaceuticals, Inc.(KALV)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-03-31.

KalVista Pharmaceuticals, Inc. (KALV) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores KALV at 12.8/100 on a 32-signal composite quality model, placing it at rank #2,781 of 2,854 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (5.3) and revenue growth (6.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 7.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), KalVista Pharmaceuticals, Inc. reports quarterly revenue of $40.9M, net income of $-23.5M, free cash flow of $-14.6M. Top institutional holders of KALV by reported 13-F value include VR Adviser, Frazier Life Sciences Management, L.P., SUVRETTA CAPITAL MANAGEMENT, based on the most recent SEC filings. KALV trades on the Nasdaq exchange and files with the SEC under CIK 1348911. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate KALV daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for KalVista Pharmaceuticals, Inc. directly from SEC EDGAR.